| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Anesthesia and Critical Care and 2 Department of Medicine, The University of Chicago, Chicago, Illinois 60637
 |
ABSTRACT |
|---|
 TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
The objective of this study was to examine the role of oxygen radicals, protein kinase C (PKC), and ATP-sensitive K+ (KATP) channels in mediating flumazenil-produced preconditioning. Chick cardiomyocyte death was quantified using propidium iodide, and oxygen radical generation was assessed using 2',7'-dichlorofluorescin oxidation. Preconditioning was initiated with 10 min of ischemia followed by 10 min of reoxygenation. Alternatively, flumazenil was infused for 10 min and removed 10 min before ischemia. Flumazenil (10 µM) and preconditioning increased oxygen radicals [1,693 ± 101 (n = 3) and 1,567 ± 98 (n = 3), respectively, vs. 345 ± 53 (n = 3) in control] and reduced cell death similarly [22 ± 3% (n = 5) and 18 ± 2% (n = 6), respectively, vs. controls 49 ± 5% (n = 8)]. Protection and increased oxygen radicals by flumazenil were abolished by pretreatment with the antioxidant thiol reductant 2-mercaptopropionyl glycine (800 µM; 52 ± 10%, n = 6). Specific PKC inhibitors Go-6976 (0.1 µM) and chelerythrine (2 µM), given during ischemia and reoxygenation, blocked flumazenil-produced protection (47 ± 5%, n = 6). The PKC activator phorbol 12-myristate 13-acetate (0.2 µM), given during ischemia and reoxygenation, reduced cell death similarly to that with flumazenil [17 ± 4% (n = 6) and 22 ± 3% (n = 5)]. Finally, 5-hydroxydecanoate (1 mM), a selective mitochondrial KATP channel antagonist given during ischemia and reoxygenation, abolished the protection of flumazenil and phorbol 12-myristate 13-acetate. Thus flumazenil mimics preconditioning to reduce cell death in cardiomyocytes. Oxygen radicals activate mitochondrial KATP channels via PKC during the process.
mitochondria; ischemia; potassium channels; GABA receptors; signal transduction
| |
INTRODUCTION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
BRIEF PERIODS OF ISCHEMIA and reperfusion make the myocardium resistant to a subsequent prolonged ischemic insult (22). Known as ischemic preconditioning, this phenomenon provides the most powerful endogenous cardioprotection yet identified (7). It would be beneficial if this powerful myocardial protection could be mimicked pharmacologically without the deleterious effects of preconditioning ischemia. Several compounds, including adenosine, ACh, and nitric oxide donors, have been shown to mimic the protective effects of preconditioning (7, 33). Reactive oxygen species (ROS), protein kinase C (PKC), and mitochondrial ATP-sensitive K+ (KATP) channels are major intracellular messengers of ischemic preconditioning (3, 14, 29). However, the signaling pathway of this endogenous cardioprotection is not fully understood.
Flumazenil is a benzodiazepine receptor antagonist that is used clinically to reverse apnea and loss of consciousness associated with oversedation (5, 18). It protects against cerebral ischemia (1, 17). Recent results from our laboratory and others suggest that ROS and KATP channels are potential cellular targets involved when flumazenil produces ischemic preconditioning in cardiomyocytes (36). We wanted to further explore the mechanism of flumazenil-induced preconditioning, specifically the role of ROS, PKC, and KATP channels, in intracellular signal transduction. For this purpose, we administered the thiol reductant 2-mercaptopropionyl glycine (2-MPG) as an antioxidant before and during the flumazenil infusion to attenuate ROS signals. In addition, we administered two PKC inhibitors and a KATP channel antagonist after the flumazenil infusion to test the hypothesis that ROS activate PKC and the KATP channel.
| |
MATERIALS AND METHODS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Cardiomyocyte preparation. Ten-day-old embryonic chick ventricular myocytes were prepared using a method first described by Barry et al. (2) and later modified by Vanden Hoek et al. (31). Briefly, hearts were harvested and placed in Hanks' balanced salt solution lacking magnesium and calcium (Life Technologies, Grand Island, NY). Ventricles were minced, and myocytes were dissociated by four to six rounds of trypsin degradation (0.025%; Life Technologies) at 37°C with gentle agitation. Then isolated cells were transferred to a solution with trypsin inhibitor for 8 min, filtered through a 100-µm mesh filter, centrifuged for 5 min at 1,200 rpm at 4°C, and finally resuspended in a medium described previously (4, 8, 31). Resuspended cells were placed in a petri dish in a humidified incubator (5% CO2-95% air at 37°C) for 45 min to promote early adherence of fibroblasts. Nonadherent cells were counted with a hemocytometer, and viability was measured using trypan blue (0.4%). Approximately 1 × 106 cells in nutritive medium were pipetted onto coverslips (25 mm) and incubated for 3-4 days, after which synchronous contractions of the monolayer were noted. Experiments were performed on spontaneously contracting cells at 3 or 4 days after isolation.
Perfusion system.
Glass coverslips containing spontaneously beating chick myocytes were
placed in a stainless steel, 1-ml, flow-through chamber (Penn Century,
Philadelphia, PA). The chamber was sealed with a Kynar film
(McMaster-Carr, Elmhurst, IL) placed between the coverslip and the
metal hypoxic chamber to minimize O2 exchange between the
chamber wall and the perfusate and then mounted on a
temperature-controlled platform (37°C) on an inverted microscope. A
water-jacketed glass equilibration column mounted above the microscope
stage was used to equilibrate the perfusate to known PO2. The standard perfusion media (Table
1) were equilibrated for 1 h before
the experiment by bubbling with 21% O2-5%
CO2-74% N2. A simulated ischemia
solution (Table 1) composed of balanced salt solution (BSS) containing
no glucose with 2-deoxyglucose (20 mM) added to inhibit glycolysis was
bubbled with 20% CO2-80% N2 for 1 h
before the experiments. The pH of the perfusion solution was routinely
verified (pH 7.4 for normoxic BSS and pH 6.8 for simulated
ischemic BSS). Stainless steel or low-O2-solubility polymer tubing connected the equilibration column to the flow-through chamber to minimize ambient O2 transfer into the perfusate.
In previous studies, the low PO2 in the chamber
was confirmed under conditions identical to those of experiments using
an optical phosphorescence quenching method (21, 24, 32)
(Oxyspot, Medical Systems, Greenvale, NY).
|
Cell viability. An inverted microscope equipped for epifluorescent illumination included a xenon light source (75 W), a 12-bit digital cooled charge coupled device camera (Princeton Instruments), a shutter and filter wheel (Sutter), and appropriate excitation and emission filter cubes. Fluorescent cell images were obtained using a ×10 objective lens (Nikon Fluor). Data were acquired and analyzed with Metamorph software (Universal Imaging). Cell viability was quantified with the nuclear stain propidium iodide (PI, 5 µM; Molecular Probes, Eugene, OR), an exclusion fluorescent dye that binds to chromatin, on loss of membrane integrity (29, 31). PI is not toxic to cells over a course of 8 h, permitting its addition to the perfusate throughout the experiments. At the completion of each experiment, digitonin (300 µM) was added to the perfusate for 1 h. Digitonin disrupted cell membrane integrity of all cells, allowing PI to enter. Percent loss of viability (cell death) was then expressed relative to the maximum value after 1 h of digitonin exposure (100%).
Measurement of ROS.
ROS generation in cells was assessed using the probe
2',7'-dichlorofluorescin (DCFH). The membrane-permeable diacetate form of the dye DCFH (DCFH-DA) was continuously present in the perfusate at
5 µM. Within the cell, esterases cleave the acetate groups on
DCFH-DA, thus trapping the reduced probe (DCFH) intracellularly (24). ROS generation in the cells leads to the oxidation
of DCFH, yielding the fluorescent product DCF (24). The
probe DCFH in cardiomyocytes is readily oxidized by
H2O2 or hydroxyl radical but is relatively
insensitive to superoxide (O
) (8, 29,
31). Fluorescence was measured using an excitation wavelength of
480 nm, dichroic 505-nm-long pass, and emitter band pass of 535 nm
(Chroma Technology) with neutral density filters to attenuate the
excitation light intensity. Fluorescence intensity was assessed in
clusters of several cells identified as regions of interest. Background
was identified as an area without cells or with minimal cellular
fluorescence. Intensity values are reported as the percentage of
initial values after background value was subtracted.
Chemicals. Flumazenil was purchased from Hoffmann-La Roche (Nutley, NJ). 2-MPG, phorbol 12-myristate 13-acetate (PMA), 5-hydroxydecanoate (5-HD), chelerythrine, ebselen, and diethyldithiocarbamic acid (DDC) were purchased from Sigma Chemical (St. Louis, MO). Go-6976 was purchased from Calbiochem-Novabiochem (San Diego, CA). Flumazenil, 2-MPG, PMA, Go-6976, and 5-HD were dissolved in BSS buffer before administration.
Experimental design.
As illustrated in Fig. 1, 13 groups of
cardiomyocytes were studied. Control cells were subjected to 60 min of
simulated ischemia followed by 3 h of reoxygenation.
Preconditioned cells underwent 10 min of ischemia followed by
10 min of reoxygenation before being subjected to the
ischemia-reoxygenation protocol used for the controls. In
vehicle control and flumazenil-treated cells, equal volumes of BSS
buffer (control) or flumazenil (10 µM) were added to the perfusate
for 10 min instead of preconditioning. In antioxidant-treated cells,
2-MPG (800 µM) was given during the 1-h equilibration period before
ischemia. In cells treated with PMA, Go-6976, chelerythrine,
and 5-HD were given during the ischemia-and-reperfusion period
to test the hypothesis that PKC and mitochondrial KATP
channels are downstream signals of flumazenil-induced ROS.
|
Statistical analysis. Values are means ± SE. Differences between groups for cell death and ROS production were compared using a two-factor ANOVA with repeated measures and Fisher's least significant difference test. Differences between groups were considered significant if P < 0.05.
| |
RESULTS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Intracellular ROS generation.
Flumazenil (10 µM) and preconditioning produced marked increases of
DCFH oxidation (an index of ROS production) compared with controls
[1,693 ± 101 and 1,567 ± 98 arbitrary units (AU),
respectively, vs. 345 ± 53 AU in controls (n = 3 in each group), P < 0.05 vs. controls; Fig.
2]. The increase of ROS signaling by
flumazenil was abolished by treatment with 2-MPG (345 ± 53, n = 3); 2-MPG alone had no effects on baseline DCFH
oxidation in the absence of preconditioning ischemia or
flumazenil (298 ± 48, n = 3).
|
Cytosol H2O2 radicals are major components
of ROS produced by flumazenil.
Figure 2B shows that flumazenil-produced ROS were abolished
by ebselen (5 µM), a glutathione peroxidase converting
H2O2 to H2O (6). The
precursor of H2O2 is O. SOD is an enzyme in cytosol that catalyzes the conversion of
O to H2O2. Interestingly,
DDC (1 mM), a cytosol Cu,Zn-SOD inhibitor, attenuated ROS production of
flumazenil. In addition, DCFH is more readily oxidized by
H2O2 than by O. Furthermore, myxothiazol (0.5 µM), a mitochondria electron transport inhibitor, did not affect ROS generation by flumazenil. These data indicate that
ROS produced by flumazenil are mainly H2O2
radicals that originate in cytosol and that cytosol SOD and glutathione
peroxidase have important roles in their generation and degradation.
Flumazenil mimics ischemic preconditioning via ROS.
In the control series, 60 min of ischemia and 3 h of
reperfusion resulted in cell death of 49 ± 5% (n = 8). Preconditioning with 10 min of ischemia and 10 min of
reoxygenation before ischemic insult markedly reduced cell
death (18 ± 2%, n = 6). Infusion of flumazenil
(10 µM) for 10 min followed by 10 min of a drug-free period reduced
cell death to the same extent (22 ± 3%, n = 5) as did preconditioning. The preconditioning effect of flumazenil was
abolished by the antioxidant 2-MPG administered during the equilibrium
before ischemic insult (52 ± 10%, n = 6;
Fig. 3).
|
2-MPG reduces cell death when administered during
ischemia-reperfusion.
The antioxidant 2-MPG reduced cell death significantly when
administered during ischemia-reperfusion [25 ± 6%
(n = 5) vs. 52 ± 10% (n = 3);
Fig. 4]. These results further confirm
that 2-MPG functions as a free radical scavenger in our model.
|
ROS signals stimulate PKC.
When administered during ischemia and reperfusion (after
flumazenil infusion), specific PKC inhibition with Go-6976 (0.1 µM) or chelerythrine (2 µM) virtually abolished the protection of flumazenil [43 ± 7% (n = 6) and 54 ± 7%
(n = 4); Fig. 5]. PKC activation with 0.2 µM PMA mimicked the protective effect (17 ± 4%, n = 6; Fig. 6). In
addition, PKC inhibitors (Go-6976 and chelerythrine), when given before
ischemia, had no effects on flumazenil-generated ROS.
|
|
PKC activation opens the mitochondrial KATP channel. The selective mitochondrial KATP channel antagonist 5-HD, which was given during the ischemia-and-reperfusion period, had no effect on cell death by itself (36), but in the present study, it abolished the protective effect of flumazenil and PMA [46 ± 5% (n = 8) and 43 ± 7% (n = 6), respectively; Fig. 6].
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
We made several novel observations in our in vitro cardiomyocyte model of simulated ischemia-reperfusion. First, a transient increase in ROS generation after 10 min of flumazenil infusion correlates with preconditioning effects that reduce cardiocyte death during ischemia and reperfusion. Second, the ROS signals with flumazenil appear to activate PKC, in that PKC inhibition abolished protection by flumazenil. Third, PKC activation opens mitochondrial KATP channels, as indicated by the ability of 5-HD to abolish protection. Our results suggest that an increase in ROS signals leads to the opening of mitochondrial KATP channels via PKC activation. This intracellular signaling is one important pathway by which flumazenil mimics ischemic preconditioning.
Initial data demonstrated that a single 10-min ischemic period before a more sustained ischemia markedly reduced cardiocyte death compared with a single 60-min period of ischemic insult (18 ± 2 vs. 49 ± 5%). Subsequently, an infusion of flumazenil for 10 min, instead of 10 min of ischemia (preconditioning), reduced cardiocyte death to an extent similar to that resulting from preconditioning (22 ± 3 and 18 ± 2%, respectively). In addition to the beneficial effects of ischemic preconditioning or flumazenil in reducing cell death, return of spontaneous contraction was markedly higher in preconditioned and flumazenil-treated cells. These results agree with our previous findings (35, 36) and those of others (29). Flumazenil mimics preconditioning to attenuate ischemia-reperfusion injury.
ROS are key intracellular messengers (27) but can potentially contribute to cell death when generated at high levels. The protection of flumazenil was abolished by pretreatment with 2-MPG, a thio reductant with antioxidant properties. This effect suggests that ROS signals are important second messengers in mediating cardioprotection. However, when 2-MPG was administered during prolonged ischemia-reperfusion, it markedly reduced cell death, likely via degrading free radicals generated during ischemia-reperfusion (15). Interestingly, we also found that flumazenil, similar to ischemic preconditioning, resulted in a marked increase in DCFH oxidation, an index of ROS production. Others have reported that ROS are involved in triggering cardioprotection of ischemic and hypoxic preconditioning (8, 29), ACh (35), and opioids (34). More importantly, we previously demonstrated that 10 min of flumazenil infusion resulted in the same pattern and magnitude of ROS signals observed during ischemic preconditioning (36). Thus these findings suggest that ROS signals are crucial in producing the protection of flumazenil.
Flumazenil-generated ROS are mainly H2O2,
because DCFH is more readily oxidized by H2O2
than by O. In addition, ROS were abolished by
ebselen, a glutathione peroxidase that converts H2O2 to H2O (6). The
precursor of H2O2 is O. SOD
is an enzyme in cytosol that catalyzes this reaction. Interestingly, DDC, a cytosol Cu,Zn-SOD inhibitor, attenuated ROS production. Thus
flumazenil-generated ROS are H2O2 present in
cytosol. However, we cannot rule out the possibility that
H2O2 were generated in mitochondria or other
subcellular sites and then transported to cytosol. ROS generated by
ischemic and hypoxic preconditioning originate from
mitochondria (29). It is reasonable to suspect that
mitochondria are the source of flumazenil-induced ROS. However, we
found that myxothiazol, a mitochondria electron transport inhibitor, did not affect ROS generation by flumazenil. Taken together, our data
indicate that ROS produced by flumazenil are mainly
H2O2 radicals that originate in cytosol (Fig.
7). Obviously, the exact mechanism by
which flumazenil generates ROS is still not clear and needs further
study.
|
Subsequently, we noticed that the cardioprotection of flumazenil was
abolished when Go-6976 or chelerythrine, specific PKC inhibitors, was
given after flumazenil infusion. This suggests that ROS with flumazenil
activate PKC. ROS signals activate PKC (10, 11), which may
mediate cardioprotection of preconditioning (13, 19, 26).
Numerous studies (3, 11, 23) have suggested that PKC is a
central mediator of preconditioning. In intact rats, inhibition of PKC
partially or completely abolished the effects of preconditioning,
depending on the strength of the preconditioning stimulus
(13). In a similar cardiomyocyte model of simulated ischemia and reperfusion, Liang (19) demonstrated
that PKC activation was an important component of signal transduction
of ischemic preconditioning and adenosine. Specific isoforms of
PKC are more important in producing cardioprotection, and translocation
of PKC (
and 
) may mediate the cardioprotective effect of
preconditioning in rats and rabbits (16, 23). In addition,
we noticed that PKC inhibition did not affect flumazenil-generated ROS.
This observation is consistent with recent results of Vanden Hoek et
al. (30), who showed that PKC inhibition with Go-6976 did
not affect ROS produced by preconditioning. Therefore, our results and
those of others strongly suggest that PKC is an important downstream signal of flumazenil-produced ROS.
ROS signals also lead to activation of mitochondrial KATP channels (8, 29), which are important in triggering and mediating the protection of preconditioning (14, 20). We found that blockade of mitochondrial KATP channels with 5-HD after flumazenil infusion abolished its protection, but our previous data showed that when 5-HD was given before and during the flumazenil infusion, free radical signals were not affected (36). Therefore, KATP channel activation is a downstream signal of flumazenil-induced ROS.
Whether PKC activation opens the KATP channel or vice versa is unclear (9, 26, 28). We noticed that the specific PKC activator PMA, administered during ischemia and reperfusion, reduced cell death to the same extent as did flumazenil. The protective effects of flumazenil and PMA were blocked by 5-HD given during ischemia and reperfusion, which suggests that flumazenil activates the mitochondrial KATP channel via PKC. PKC enhances the ability of diazoxide to open the mitochondrial KATP channel in rabbit cardiomyocytes (25). Our results therefore suggest that PKC activates the mitochondrial KATP channel in the protection of flumazenil. The mechanism by which mitochondrial KATP channel activation produces cardioprotection has not been established (3). In a recent review article, Gross and Fryer (14) suggested that activation of the mitochondrial KATP channel leads to entry of potassium ion into the mitochondria and intramitochondrial depolarization. This action could decrease mitochondrial calcium overload and cause matrix swelling, which enhances mitochondrial energy synthesis and respiration (3).
The mechanism of preconditioning is complicated and not fully established. Multiple signaling pathways, including adenosine, ACh, KATP channels, ROS, PKC, and other kinases, are involved in the cardioprotection of preconditioning (7, 28). Results of this study addressed only the importance of ROS-PKC-mitochondrial KATP channel signaling pathway in flumazenil-induced preconditioning protection. The recent study by Vanden Hoek et al. (30) showed that adenosine had no effects on ROS production before ischemia, which further suggests that, in addition to ROS-PKC-KATP channel signal transduction, other parallel signaling pathways exist by which preconditioning and flumazenil protect cardiomyocytes in ischemia-reperfusion.
In conclusion, we showed that flumazenil mimics ischemic preconditioning to reduce cell death in cultured cardiomyocytes. Transiently increased ROS signals (likely H2O2) with flumazenil that activate mitochondrial KATP channels via PKC appear to explain how flumazenil mimics ischemic preconditioning. Our data also suggest that clinical use of flumazenil could be beneficial for patients with ischemic heart disease.
| |
ACKNOWLEDGEMENTS |
|---|
The authors express sincere appreciation to Sally Kozlik for editorial assistance.
| |
FOOTNOTES |
|---|
This study was supported by National Heart, Lung, and Blood Institute Grant HL-03881-02.
Address for reprint requests and other correspondence: Z. Yao, Dept. of Anesthesia and Critical Care, The University of Chicago, 5841 S. Maryland Ave., MC 4028, Chicago, IL 60637 (E-mail: zyao{at}airway2.uchicago.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 24 May 2000; accepted in final form 11 September 2000.
| |
REFERENCES |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
1.
Auta, J,
Romeo E,
Kozikowski A,
Ma D,
Costa E,
and
Guidotti A.
Participation of mitochondrial diazepam binding inhibitor receptors in the anticonflict, antineophobic and anticonvulsant action of 2-aryl-3-indoleacetamide and imidazopyridine derivatives.
J Pharmacol Exp Ther
265:
649-656,
1993
2.
Barry, WH,
Pober J,
Marsh JD,
Frankel SR,
and
Smith TW.
Effects of graded hypoxia on contraction of cultured chick embryo ventricular cells.
Am J Physiol Heart Circ Physiol
239:
H651-H657,
1980.
3.
Brooks, G,
and
Hearse DJ.
Role of protein kinase C in ischemic preconditioning: player or spectator?
Circ Res
79:
627-630,
1996.
4.
Chandel, NS,
Budinger GRS,
and
Schumacker PT.
Molecular oxygen modulates cytochrome c oxidase function.
J Biol Chem
271:
18672-18677,
1996
5.
Croughwell, ND,
Reves JG,
Will CJ,
Kasson BJ,
and
Goodman DK.
Safety of rapid administration of flumazenil in patients with ischaemic heart disease.
Acta Anaesthesiol Scand Suppl
92:
55-58,
1990[Medline].
6.
Dikalov, S,
Khramtsov V,
and
Zimmer G.
Determination of rate constants of the reactions of thiols with superoxide radical by electron paramagnetic resonance: critical remarks on spectrophotometric approaches.
Arch Biochem Biophys
326:
207-218,
1996[Web of Science][Medline].
7.
Downey, JM.
Ischemic preconditioning: nature's own cardioprotective intervention.
Trends Cardiovasc Med
2:
170-176,
1992[Web of Science].
8.
Duranteau, J,
Chandel NS,
Kulisz A,
Shao Z,
and
Schumacker PT.
Intracellular signaling by reactive oxygen species during hypoxia in cardiomyocytes.
J Biol Chem
273:
11619-11624,
1998
9.
Fryer, RM,
Schultz JE,
Hsu AK,
and
Gross GJ.
Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts.
Am J Physiol Heart Circ Physiol
276:
H1229-H1235,
1999
10.
Gopalakrishna, R,
and
Anderson WB.
Ca2+- and phospholipid-independent activation of protein kinase C by selective oxidative modification of the regulatory domain.
Proc Natl Acad Sci USA
86:
6758-6762,
1989
11.
Gopalakrishna, R,
Gundimeda U,
Anderson WB,
Colburn NH,
and
Slaga TJ.
Tumor promoter benzoyl peroxide induces sulfhydryl oxidation in protein kinase C: its reversibility is related to the cellular resistance to peroxide-induced cytotoxicity.
Arch Biochem Biophys
363:
246-258,
1999[Web of Science][Medline].
12.
Goto, M,
Cohen MV,
and
Downey JM.
The role of protein kinase C in ischemic preconditioning.
Ann NY Acad Sci
793:
177-190,
1996[Medline].
13.
Goto, M,
Liu Y,
Yang XM,
Ardell JL,
Cohen MV,
and
Downey JM.
Role of bradykinin in protection of ischemic preconditioning in rabbit hearts.
Circ Res
77:
611-621,
1995
14.
Gross, GJ,
and
Fryer RM.
Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning.
Circ Res
84:
973-979,
1999
15.
Horwitz, LD,
Fennessey PV,
Shikes RH,
and
Kong Y.
Marked reduction in myocardial infarct size due to prolonged infusion of an antioxidant during reperfusion.
Circulation
89:
1792-1801,
1994
16.
Kawamura, S,
Yoshida K,
Miura T,
Mizukami Y,
and
Matsuzaki M.
Ischemic preconditioning translocates PKC- and - which mediate functional protection in the isolated rat heart.
Am J Physiol Heart Circ Physiol
275:
H2266-H2271,
1998
17.
Kinnally, KW,
Zorov DB,
Antonenko YN,
Snyder SH,
McEnery MW,
and
Tedeschi H.
Mitochondrial benzodiazepine receptor linked to inner membrane ion channels by nanomolar actions of ligands.
Proc Natl Acad Sci USA
90:
1374-1378,
1993
18.
Kochs, E,
Roewer N,
Peter A,
and
Schulte am Esch J.
Effect of flumazenil on global cerebral blood flow and on intracranial pressure in the reperfusion phase following incomplete global cerebral ischemia.
Anaesth Intensivther Notf Med
23:
159-162,
1988.
19.
Liang, BT.
Protein kinase C-mediated preconditioning of cardiac myocytes: roles of adenosine receptor and KATP channel.
Am J Physiol Heart Circ Physiol
273:
H847-H853,
1997
20.
Liu, Y,
Sato T,
Seharaseyon J,
Szewczyk A,
O'Rourke B,
and
Marban E.
Mitochondrial ATP-dependent potassium channels. Viable candidate effectors of ischemic preconditioning.
Ann NY Acad Sci
874:
27-37,
1999[Web of Science][Medline].
21.
Lo, LW,
Koch CJ,
and
Wilson DF.
Calibration of oxygen-dependent quenching of the phosphorescence of Pd-meso-tetra(4-carboxyphenyl)porphine: a phosphor with general application for measuring oxygen concentration in biological systems.
Anal Biochem
236:
153-160,
1996[Web of Science][Medline].
22.
Murry, CE,
Jennings RB,
and
Reimer KA.
Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.
Circulation
74:
1124-1136,
1986
23.
Ping, P,
Zhang J,
Qui Y,
Tang XL,
Manchikalapudi S,
Cao X,
and
Bolli R.
Ischemic preconditioning induces selective translocation of protein kinase C isoforms and 
in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity.
Circ Res
81:
404-414,
1997
24.
Rothe, G,
and
Valet G.
Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2',7'-dichlorofluorescin.
J Leukoc Biol
47:
440-448,
1990[Abstract].
25.
Sato, T,
O'Rourke B,
and
Marban E.
Modulation of mitochondrial ATP-dependent K+ channels by protein kinase C.
Circ Res
83:
110-114,
1998
26.
Simkhovich, BZ,
Przyklenk K,
and
Kloner RA.
Role of protein kinase C as a cellular mediator of ischemic preconditioning: a critical review.
Cardiovasc Res
40:
9-22,
1998
27.
Suzuki, YJ,
Forman HJ,
and
Sevanian A.
Oxidants as stimulators of signal transduction.
Free Radic Biol Med
22:
269-285,
1997[Web of Science][Medline].
28.
Takashi, E,
Wang Y,
and
Ashraf M.
Activation of mitochondrial KATP channel elicits late preconditioning against myocardial infarction via protein kinase C signaling pathway.
Circ Res
85:
1146-1153,
1999
29.
Vanden Hoek, TL,
Becker LB,
Shao Z,
Li C,
and
Schumacker PT.
Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes.
J Biol Chem
273:
18092-18098,
1998
30.
Vanden Hoek, TL,
Becker LB,
Shao Z,
Li C,
and
Schumacker PT.
Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion.
Circ Res
86:
541-548,
2000
31.
Vanden Hoek, TL,
Shao Z,
Li C,
Zak R,
Schumacker PT,
and
Becker LB.
Reperfusion injury on cardiac myocytes after simulated ischemia.
Am J Physiol Heart Circ Physiol
270:
H1334-H1341,
1996
32.
Wilson, DF,
Rumsey WL,
Green TJ,
and
Vanderkooi JM.
The oxygen dependence of mitochondrial oxidative phosphorylation measured by a new optical method for measuring oxygen concentration.
J Biol Chem
263:
2712-2718,
1988
33.
Yao, Z,
and
Gross GJ.
The ATP-dependent potassium channel: an endogenous cardioprotective mechanism.
J Cardiovasc Pharmacol
24 Suppl4:
S28-S34,
1994.
34.
Yao Z and McPherson BC. Morphine mimics preconditioning via free
radical signals and mitochondrial KATP channels in
myocytes. Circulation. In press.
35.
Yao, Z,
Tong J,
Tan X,
Li C,
Shao Z,
Kim WC,
Vanden Hoek TL,
Becker LB,
Head CA,
and
Shumacker PT.
Role of reactive oxygen species in acetylcholine-induced preconditioning in cardiomyocytes.
Am J Physiol Heart Circ Physiol
277:
H2504-H2509,
1999
36.
Zhang, Q,
and
Yao Z.
Flumazenil preconditions cardiomyocytes via oxygen radicals and KATP channels.
Am J Physiol Heart Circ Physiol
279:
H1858-H1863,
2000
This article has been cited by other articles:
|
|
 |
|
  L. Willems, K. J. Ashton, and J. P. Headrick Adenosine-mediated cardioprotection in the aging myocardium Cardiovasc Res, May 1, 2005; 66(2): 245 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sarre, N. Lange, P. Kucera, and E. Raddatz mitoKATP channel activation in the postanoxic developing heart protects E-C coupling via NO-, ROS-, and PKC-dependent pathways Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1611 - H1619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hassouna, B. M. Matata, and M. Galinanes PKC-{epsilon} is upstream and PKC-{alpha} is downstream of mitoKATP channels in the signal transduction pathway of ischemic preconditioning of human myocardium Am J Physiol Cell Physiol, November 1, 2004; 287(5): C1418 - C1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Headrick, B. Hack, and K. J. Ashton Acute adenosinergic cardioprotection in ischemic-reperfused hearts Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1797 - H1818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zaugg, E. Lucchinetti, C. Garcia, T. Pasch, D. R. Spahn, and M. C. Schaub Anaesthetics and cardiac preconditioning. Part II. Clinical implications Br. J. Anaesth., October 1, 2003; 91(4): 566 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. YELLON and J. M. DOWNEY Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology Physiol Rev, October 1, 2003; 83(4): 1113 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Peart and J. P Headrick Adenosine-mediated early preconditioning in mouse: protective signaling and concentration dependent effects Cardiovasc Res, June 1, 2003; 58(3): 589 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Peart, L. Willems, and J. P. Headrick Receptor and non-receptor-dependent mechanisms of cardioprotection with adenosine Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H519 - H527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Y. Zhang, B. C. McPherson, H. Liu, T. S. Baman, P. Rock, and Z. Yao H2O2 opens mitochondrial KATP channels and inhibits GABA receptors via protein kinase C-epsilon in cardiomyocytes Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1395 - H1403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Liu, B. C. McPherson, X. Zhu, M. L. A. Da Costa, V. Jeevanandam, and Z. Yao Role of nitric oxide and protein kinase C in ACh-induced cardioprotection Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H191 - H197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Minners, L. Lacerda, J. McCarthy, J. J. Meiring, D. M. Yellon, and M. N. Sack Ischemic and Pharmacological Preconditioning in Girardi Cells and C2C12 Myotubes Induce Mitochondrial Uncoupling Circ. Res., October 26, 2001; 89(9): 787 - 792. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
